-

NATIONAL VISION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of National Vision Holdings, Inc. - EYE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into National Vision Holdings, Inc. (NasdaqGS: EYE).

On May 10, 2022, the Company disclosed deeply disappointing financial and operational results for its first fiscal quarter of 2022 including a 1.2% decrease in net revenues to $527.7 million, a 30.6% decrease in net income to $30.1 million, and a 28.2% decrease in diluted EPS to $0.34, as well as numerous cuts to its 2022 outlook.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains pending.

KSF’s investigation is focusing on whether National Vision’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of National Vision shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-eye/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:EYE

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Leggett & Platt Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Leggett & Platt, Incorporated - LEG

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Leggett & Platt, Incorporated (NYSE: LEG) to Somnigroup International Inc. (NYSE: SGI). Under the terms of the proposed transaction, shareholders of Leggett will receive 0.1455 shares of Somnigroup common stock for each share of Leggett & Platt that they own. KSF is seeking to determine wheth...

Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Assertio Holdings, Inc. (NasdaqCM: ASRT) to Garda Therapeutics. Under the terms of the proposed transaction, shareholders of Assertio will receive $18.00 per share in cash and a contingent value right. KSF is seeking to determine whether this consideration and the process that led to it are adequate...

Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NasdaqGS: OFIX). On September 12, 2023, the Company announced the appointment of an interim CEO, interim CFO, and interim CLO, effective immediately, following the “unanimous decision by the Board’s independent di...
Back to Newsroom